Prescription medicine
Vasopressin Brand names: Vasostrict
Vasopressin (Vasostrict) is a prescription medicine with an FDA approval on record since 2014. FDA's NDC Directory lists it from 10 generic labelers.
- Generic listed
Check it at the source: the vasopressin FDA label on DailyMed (effective February 21, 2025, Baxter Healthcare Corporation); the NDA 204485 record on Drugs@FDA; every vasopressin label on DailyMed.
Highlights of the record
FDA label of February 21, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageVasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Forms and strengths
- 100ml
Injection; injection (solution); solution.
On the market
- Earliest approval on file
- April 17, 2014 Vasostrict, Ph Health; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 10 first December 15, 2021; 9 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 16 of which 10 under generic applications, 8 under brand applications, repackagers included
- Last listed patent
- January 30, 2035 Vasostrict injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 10 since 2018 0 Class I among all firms' recalls; latest August 6, 2026; 2 more by firms not listed as its makers
- FAERS reports
- 4,355 through July 30, 2026
What is vasopressin used for?
From the label: indications and usageVasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin in Sodium Chloride Injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
Source: FDA drug label (Vasopressin in 0.9% Sodium Chloride), Baxter Healthcare Corporation, effective February 21, 2025 (SPL set b5b2c367-6b7e-40be-a296-c4632f3e783f), via openFDA; the full label on DailyMed
Is there a generic for vasopressin (Vasostrict)?
The FDA approved the first generic vasopressin on December 15, 2021. 10 generic applications are approved; 9 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists vasopressin from 10 labelers under a generic (ANDA) application and from 8 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 15 patents for Vasostrict injection, the last expiring on January 30, 2035; a patent listed only for Vasopressin In Sodium Chloride 0.9% injection runs to September 27, 2044. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2014 earliest approval on file
- 2021 first generic approved
- 2035 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Has vasopressin been recalled?
The FDA's Enforcement Report lists 12 recalls naming vasopressin since 2018: 0 Class I (the most serious), 11 Class II, 1 Class III; 6 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of vasopressin and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| August 6, 2026 | Class II | Baxter Healthcare Corporation | CGMP Deviations |
| May 18, 2026 | Class II | IntegraDose Compounding Services LLC not a listed maker | Subpotent Drug |
| May 13, 2024 | Class II | American Regent, Inc. | Subpotent product in addition to having out-of-specification results for impurities. |
| January 22, 2024 | Class II | IntegraDose Compounding Services LLC not a listed maker | Sub-potent drug: failure to maintain potency through the duration of the labeled expiration/beyond-use date. |
| January 12, 2024 | Class II | IntegraDose Compounding Services LLC | Subpotent Drug |
| January 11, 2024 | Class II | Par Sterile Products LLC | Superpotent Drug: Assay from the 3-month and 6-month stability intervals exceeded the upper specification limit. |
| April 28, 2023 | Class II | Central Admixture Pharmacy Services, Inc. | Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile. |
| December 14, 2020 | Class II | SCA Pharmaceuticals, Inc. | Subpotent drug. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the vasopressin label say about other medicines?
The vasopressin label names 13 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Clozapine | drug interactions | Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin in Sodium Chloride Injection. |
| Cyclophosphamide | drug interactions | Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in … |
| Demeclocycline | drug interactions | Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin in Sodium Chloride Injection. |
| Desmopressin | warnings and precautions | Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts. |
| Enalapril | drug interactions | Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in … |
| Felbamate | drug interactions | Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in … |
| Foscarnet | drug interactions | Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin in Sodium Chloride Injection. |
| Haloperidol | drug interactions | Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in … |
| Ifosfamide | drug interactions | Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in … |
| Indomethacin | drug interactions | Indomethacin may prolong effects of Vasopressin in Sodium Chloride Injection. |
| Lithium | drug interactions | Suspected of Causing Diabetes Insipidus Use with drugs suspected of causing diabetes insipidus (e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of Vasopressin in Sodium Chloride Injection. |
| Methyldopa | drug interactions | Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in … |
| Vincristine | drug interactions | Suspected of Causing SIADH Use with drugs suspected of causing SIADH (e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of Vasopressin in … |
Source: FDA drug label (Vasopressin in 0.9% Sodium Chloride), Baxter Healthcare Corporation, effective February 21, 2025 (SPL set b5b2c367-6b7e-40be-a296-c4632f3e783f), via openFDA; the full label on DailyMed
What do FAERS reports show for vasopressin?
The FDA Adverse Event Reporting System holds 4,355 reports that list vasopressin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,717 are coded as a death and 2,520 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Vasopressin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other